Biomarin Pharmaceutical Inc

BioMarin Pharmaceutical agreed to acquire clinical-stage biotech Alesta Therapeutics for $275 million upfront, with up to $215 million in additional milestone payments. The deal gives BioMarin access to Alesta's lead asset ALE1, a potential oral therapy for the rare genetic bone disease hypophosphatasia. Barclays raised its price target on BioMarin to $111 from $105, and Piper Sandler lifted its target to $88 from $82, both maintaining Overweight ratings, while H.C. Wainwright lowered its target to $59 from $60 with a Neutral rating. BioMarin shares closed at $69.33, up 3.5%.

BioMarin Pharmaceutical raised its full-year 2026 revenue guidance to between US$3.88 billion and US$3.93 billion and filed a US$719.24 million common stock shelf registration for an ESOP-related offering. The company reported second-quarter 2026 revenue of US$989.71 million and provided more detailed third and fourth quarter expectations, with the higher outlook leaning on a stronger fourth quarter and Amicus contribution. The raised guidance modestly reinforces the near-term growth catalyst but does little to reduce the key risk around rising costs outpacing revenue and the potential need for further dilutive financing if performance weakens. Some of the lowest analysts were already cautious, assuming about US$4.5 billion revenue and US$752.9 million earnings by 2029, focusing heavily on pricing and reimbursement risk.

BioMarin Pharmaceutical has updated its guidance and filed a shelf registration, alongside reporting second quarter 2026 results. The company's share price stands at US$67.36, with a 90-day return of 35.62% and a 1-year total shareholder return of 17.07%, though the 3-year total shareholder return is down 24.36%. Analysts expect earnings to reach $1.3 billion, or $6.72 per share, by about June 2029, up from $268.7 million today, with estimates ranging from $759.4 million to $2.1 billion. A discounted cash flow analysis using a 7.32% discount rate suggests a fair value of $87.85, implying the stock is 23.3% undervalued.

The FDA has accepted BioMarin Pharmaceutical's supplemental New Drug Application for VOXZOGO, setting a target decision date of February 28, 2027. The stock has seen a 5.81% return over the past 30 days and a 6.72% return over 90 days, though the three-year total shareholder return remains down 31.69%. A widely followed narrative values the company at a fair value of $87.85 per share, implying a 33% upside from the last close of $59.20, driven by strong revenue growth from therapies like VOXZOGO and VIMIZIM, pipeline advances including late-stage programs for achondroplasia and ENPP1 deficiency, and expanding addressable markets through improved genetic diagnosis. However, the current price-to-earnings ratio of 42.6 times is above both the US biotech industry average of 17.4 times and a fair ratio of 27.5 times, indicating valuation risk if sentiment shifts.

The U.S. Food and Drug Administration has accepted BioMarin Pharmaceutical's supplemental New Drug Application seeking full approval of its achondroplasia treatment Voxzogo. The FDA set an action date of February 28, 2027. The application is supported by three long-term trials. Voxzogo was granted accelerated approval in 2021.

StockStory identifies two cash-heavy stocks with exciting potential and one to ignore. DocuSign, with a net cash position of $630.8 million representing 7.4% of its market cap, is flagged as a sell due to underwhelming annual recurring revenue growth of 8.5% and high competitive spending. Comfort Systems, holding $1.01 billion in net cash or 1.6% of market cap, is viewed bullishly thanks to 53.1% average backlog growth over two years and a 9.5 percentage point increase in free cash flow margin over five years. BioMarin Pharmaceutical, with $782.8 million in net cash equating to 7.3% of market cap, is favored for its 14.5% annual revenue growth over two years and projected 28.4% revenue increase. Comfort Systems trades at $1,857 per share and 45.7 times forward earnings, while BioMarin is at $56.05 per share and 10.2 times forward earnings.

StockStory has identified BioMarin Pharmaceutical and Boston Scientific as two healthcare stocks poised for long-term outperformance, while recommending investors avoid ICU Medical. BioMarin, which develops therapies for rare genetic disorders, posted 14.5% annual sales growth over the past two years and is projected to accelerate to 28.4% revenue growth in the next twelve months, with its free cash flow margin expanding by 5.6 percentage points over five years. Boston Scientific, a maker of minimally invasive medical devices, achieved 15.7% organic revenue growth and grew earnings per share at a 24.2% annual rate over five years, supported by a 9.1 percentage point increase in free cash flow margin. In contrast, ICU Medical saw sales decline 1.6% annually over two years, earnings per share growth of just 2.9% annually over five years trailing revenue gains, and a return on invested capital of only 0.9%, signaling weak profitability and investment challenges.

BioMarin Pharmaceutical presented new clinical data at ENDO 2026 showing that three years of treatment with VOXZOGO led to sustained improvements in annualized growth velocity and height standard deviation scores for children with hypochondroplasia in an investigator-led Phase 2 extension study. The company plans to submit a supplemental New Drug Application to the FDA in the third quarter of 2026, building on recent positive Phase 3 results. BioMarin also shared Phase 1 data for BMN 333, an investigational long-acting C-type natriuretic peptide for achondroplasia, with a single-ascending dose study demonstrating sustained systemic exposure that supports a potential weekly dosing schedule. The treatment was well tolerated and significantly increased free CNP exposure compared to existing therapies, and enrollment is underway for a registration-enabling Phase 2/3 study.